Evidence mapPaperPMID 41550528Full record

ArticleKidney international reports2026

International Environmental Impact of CKD Care.

Katherine A Barraclough, Aleix Cases, Matthew J Eckelman, Celine Germond-Duret, Carmine Zoccali, Nina Embleton, Antony Wright, Luke Hubbert, Lindsay Nicholson, Salvatore Barone and 4 more

Abstract read
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Katherine A BarracloughDepartment of Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Aleix CasesNephrology Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
Matthew J EckelmanDepartment of Civil and Environmental Engineering, Northeastern University, Boston, Massachusetts, USA.
Celine Germond-DuretSchool of Global Affairs, Lancaster University, Lancaster, UK.
Carmine ZoccaliRenal Research Institute, New York, New York, USA.
Nina EmbletonMaverex Limited, Newcastle upon Tyne, UK.
Antony WrightMaverex Limited, Newcastle upon Tyne, UK.
Luke HubbertMaverex Limited, Newcastle upon Tyne, UK.
Lindsay NicholsonMaverex Limited, Newcastle upon Tyne, UK.
Salvatore BaroneGlobal Medical Affairs, AstraZeneca, Boston, Massachusetts, USA.
Claudia CabreraEmerging Medicines, BioPharmaceutical Medical AstraZeneca, Gothenburg, Sweden.
Juan Jose Garcia SanchezGlobal Market Access and Pricing, AstraZeneca, Barcelona, Spain.
Viknesh SelvarajahResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Roberto Pecoits-FilhoClin Epi Program Area, Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Data reporting the environmental impact of the overall chronic kidney disease (CKD) care pathway are limited. Methods: We performed a life cycle assessment (LCA) of CKD stages 1 to 5, with a primary focus on greenhouse gas (GHG) emissions and a secondary aim of quantifying broader environmental effects. The main scope estimated annual environmental impacts in the USA and UK, both per patient and for the total CKD population, with 8 additional countries included in exploratory analyses. Model inputs (annual health care resource use; travel distance; energy mix; and heating, cooling, and lighting requirements) were country-specific, where available. Environmental impacts by stage were calculated using the ReCiPe impact assessment method. Results: In the USA and UK, annual per-patient GHG emissions increased with CKD stage, from 1.9 to 7.8 tonnes and 0.4 to 5.1 tonnes of carbon dioxide equivalents (CO Conclusion: This research provides insights into the overall environmental burden of CKD and impact hotspots, enabling the development of targeted interventions that reduce emissions.

Indexed as

chronic kidney diseaseenvironmental impactgreenhouse gas emissionskidney replacement therapylife cycle assessment

Identifiers

PMID41550528
PMCPMC12805029

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.